Ocugen Inc
$ 1.87
0.54%
26 Feb - close price
- Market Cap 608,815,000 USD
- Current Price $ 1.87
- High / Low $ 1.94 / 1.81
- Stock P/E N/A
- Book Value 0.01
- EPS -0.22
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.64 %
- ROE -2.90 %
- 52 Week High 1.96
- 52 Week Low 0.52
About
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$9.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-04 | 2025-05-12 | 2025-03-31 | 2024-11-08 | 2024-08-08 | 2024-05-14 | 2024-02-07 | 2023-11-09 | 2023-08-21 | 2023-05-05 | 2023-02-28 |
| Reported EPS | -0.07 | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 | -0.05 | -0.03 | -0.06 | -0.08 | -0.07 | -0.1 |
| Estimated EPS | -0.056 | -0.06 | -0.06 | -0.0533 | -0.05 | -0.05 | -0.06 | -0.06 | -0.07 | -0.07 | -0.11 | -0.1 |
| Surprise | -0.014 | 0.01 | 0.01 | 0.0033 | 0 | 0.01 | 0.01 | 0.03 | 0.01 | -0.01 | 0.04 | 0 |
| Surprise Percentage | -25% | 16.6667% | 16.6667% | 6.1914% | 0% | 20% | 16.6667% | 50% | 14.2857% | -14.2857% | 36.3636% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCGN
2026-02-24 11:51:30
Ocugen Inc. (Nasdaq: OCGN) will hold a conference call and live webcast on Wednesday, March 4, 2026, at 8:30 a.m. Eastern to discuss its fourth-quarter and full-year 2025 financial results and provide a business update. The company will release its earnings results before the market opens on that day. Ocugen is a biotechnology company focused on developing gene therapies for blindness-related diseases.
2026-02-20 21:34:17
Ocugen, Inc. (NASDAQ: OCGN) has announced significant updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team. These appointments aim to enhance external guidance from key opinion leaders and strengthen internal expertise as the company advances its gene therapy programs for blindness diseases. The company is pursuing a goal of three Biologics License Applications (BLAs) in the next three years.
2026-02-18 14:27:45
Ocugen has announced the appointment of Rita Johnson-Greene as its new chief financial officer. This move is expected to bring new financial leadership to the company.
2026-02-18 12:27:45
Ocugen, Inc. announced it will host a conference call and live webcast on Wednesday, March 4, 2026, at 8:30 a.m. ET to discuss its fourth-quarter and full-year 2025 financial results and provide a business update. A pre-market earnings announcement will be issued on the same day. The company is a biotechnology leader focused on gene therapies for blindness diseases.
2026-02-18 12:27:45
Ocugen, Inc. (OCGN) announced it will host a conference call and live webcast on March 4, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and provide a business update. The biotechnology company, focused on gene therapies for blindness, will issue a pre-market earnings announcement the same day. The call is accessible via dial-in numbers or webcast, with a replay available on their investor site.
2026-02-18 11:57:14
Ocugen, Inc. announced it will host a conference call and live webcast on Wednesday, March 4, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a business update. The company, a biotechnology leader in gene therapies for blindness, will issue a pre-market earnings announcement on the same day. Participants can access the call via dial-in numbers or a webcast on Ocugen's investor site.
